DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Cediranib is an investigational drug.
There have been 98 clinical trials for Cediranib. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2008.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and NCIC Clinical Trials Group.
Recent Clinical Trials for Cediranib
|Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer||National Cancer Institute (NCI)||Phase 2|
|Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer||M.D. Anderson Cancer Center||Phase 2|
|WIRE - Novel Treatments in Renal Cell Cancer||AstraZeneca||Phase 2|